Skip to main content

Insights on Pharmaceuticals & Medical Products


Leadership in a crisis: Responding to the coronavirus outbreak and future challenges

– For many executives, the coronavirus pandemic is a crisis unlike any other in recent times. Five leadership practices can help you respond effectively.

Biopharma portfolio strategy in the era of cell and gene therapy

– Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Understanding investment... opportunities and entry strategies will help guide their portfolio decisions.

Accelerating progress in cancer care: Perspectives from six oncology leaders

– McKinsey recently spoke to industry leaders in oncology research and cancer care to ask about their vision of the future for oncology.

The promise of digital therapeutics

– Investments in digital-therapeutics companies in the United States have grown, on average, by 40 percent a year over the past... seven years. What lies ahead for this fast-moving sector?
Executive Briefing

COVID-19: Implications for business

– The coronavirus outbreak is first and foremost a human tragedy, affecting hundreds of thousands of people. It is also having a... growing impact on the global economy. This article is intended to provide business leaders with a perspective on the evolving situation and implications for their companies. The outbreak is moving quickly, and some of the perspectives in this article may fall rapidly out of date. This article reflects our perspective as of March 30, 2020. We will update it regularly as the outbreak evolves.

Playing to win in oncology: Key capabilities for success

– Five key trends are driving growth in oncology. To be successful in oncology, a focus on capabilities is critical—both the ones... in place today and the ones needed to stay competitive.

Digital therapeutics and pharma: A blueprint for success from Sanofi’s Bozidar Jovicevic

– Sanofi’s global head of digital therapeutics talks about the benefits of digital therapeutics in improving health outcomes... in patients.
Article - McKinsey Quarterly

A game plan for quantum computing

– Thanks to technology advances, some companies may reap real gains from quantum computing within five years. What should you do... to prepare for this next big wave in computers?

Data and culture as stepping stones for Digital@Scale

– Pharma and medtech companies around the world have been building up their in-house capabilities in digital and advanced analytics,... but five challenges to implementing a digital strategy persist.

Special Collection

The Rise of Health Technology

Health technology continues to push the boundaries of how healthcare is delivered and has the power to create breakthroughs in our understanding of disease. This collection of articles and interviews explores the evolving role of health technology in the life-sciences sector and implications for key stakeholders. Contact us to learn more about our work in this field.

Want to learn more about how we help clients in Pharmaceuticals & Medical Products?

More insights


Unlocking the power of translational medicine

– By strengthening current translational medicine (TM) practices and preparing for advances, organizations could enhance the power... of TM and increase its influence on R&D productivity overall.

Big, bigger, biggest data: CTO Peter Løngreen on Denmark’s national genome project

– All for one, and one for all: Denmark’s new technological and institutional infrastructure allows for genome sequencing... at scale, opening doors for clinicians and researchers. Here’s a look at a nation’s journey to precision medicine.

The technology imperative for life sciences

– Digital disruption has reached the healthcare sector, and with it comes an imperative for life-science companies to retool core... technology to remain competitive. Here are ten guidelines for success.

The rise of the next-generation launch room

– Leading pharma companies are using their launch rooms not just to prepare for product launches, but as labs to experiment with... design thinking, agile approaches, and advanced analytics.

Rethinking manufacturing and distribution networks in medtech

– Changes in the medtech market have left many companies struggling with their operational footprints. A network redesign can help... them save costs, increase flexibility, and create a competitive edge.

Driving the next wave of innovation in CAR T-cell therapies

– Unlocking the full potential of CAR T-cell therapies requires investment in four areas.

The pursuit of excellence in new-drug development

– Innovations in biomedical sciences and technology fuel the opportunity to transform R&D for new-drug development holistically—500... days faster, better tailored to patient needs, and 25 percent cheaper.

Bioelectronics ‘jump-start’ the next wave of device therapeutics

– Blurring the lines between pharmaceuticals and medical technology, cybermedicine has the potential to become a pillar of medical... treatment and play a key role in the future of medtech innovation.

Gene therapy coming of age: Opportunities and challenges to getting ahead

– Amid breakthroughs in gene editing, the pharma industry must recalibrate its development and reimbursement model for therapies... that go beyond the traditional approach to disease treatment.

An engineering approach to derisking R&D for novel drug modalities

– Borrowing from the field of engineering, applying a “failure modes analysis” can quickly take some unnecessary risk... out of a development program for innovative modalities.

Infographic: European biotech financing is maturing, but the gap with the United States keeps growing

– How much financing is needed to encourage growth in Europe’s biotech sector? The analysis in our latest report, “ href="/industries/pharmaceuticals-and-medical-products/our-insights/biotech-in-europe-a-strong-foundation-for-growth-and-innovation">Biotech in Europe: A strong foundation for growth and innovation,” shows that investment in European biotechs is increasing. In late-stage financing, however, Europe lags behind the United States by a large (and still growing) margin—the US sector receives almost five times as much private funding as its European counterpart does. But overall, European biotechs have been good value for investors, and financing is maturing.
Sorry, we couldn't find any results. Try removing some filters.

Connect with our Pharmaceuticals & Medical Products Practice